The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Rituxan (Rituximab) Monoclonal Antibody Market Research Report 2024

Global Rituxan (Rituximab) Monoclonal Antibody Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1739066

No of Pages : 73

Ask Your Query

Synopsis
RITUXAN® (rituximab) is a prescription medicine used to treat: Adults with Non-Hodgkin's Lymphoma (NHL): alone or with other chemotherapy medicines. Children 6 months of age and older with mature B-cell Non-Hodgkin's Lymphoma (NHL) and mature B-cell acute leukemia (B-AL): in combination with chemotherapy medicines.

Global Rituxan (Rituximab) Monoclonal Antibody market is projected to reach US$ 5306.7 million in 2029, increasing from US$ 4125 million in 2022, with the CAGR of 3.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rituxan (Rituximab) Monoclonal Antibody market research.

Key manufacturers engaged in the Rituxan (Rituximab) Monoclonal Antibody industry include Roche, Teva, Pfizer and Amgen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Rituxan (Rituximab) Monoclonal Antibody were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Rituxan (Rituximab) Monoclonal Antibody market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Rituxan (Rituximab) Monoclonal Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Roche
  • Teva
  • Pfizer
  • Amgen

Segment by Type

  • Brand
  • Biosimilar

Segment by Application

  • Child
  • Adult

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Rituxan (Rituximab) Monoclonal Antibody report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Rituxan (Rituximab) Monoclonal Antibody Market Overview
1.1 Product Overview and Scope of Rituxan (Rituximab) Monoclonal Antibody
1.2 Rituxan (Rituximab) Monoclonal Antibody Segment by Type
1.2.1 Global Rituxan (Rituximab) Monoclonal Antibody Market Value Comparison by Type (2023-2029)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Rituxan (Rituximab) Monoclonal Antibody Segment by Application
1.3.1 Global Rituxan (Rituximab) Monoclonal Antibody Market Value by Application: (2023-2029)
1.3.2 Child
1.3.3 Adult
1.4 Global Rituxan (Rituximab) Monoclonal Antibody Market Size Estimates and Forecasts
1.4.1 Global Rituxan (Rituximab) Monoclonal Antibody Revenue 2018-2029
1.4.2 Global Rituxan (Rituximab) Monoclonal Antibody Sales 2018-2029
1.4.3 Global Rituxan (Rituximab) Monoclonal Antibody Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Rituxan (Rituximab) Monoclonal Antibody Market Competition by Manufacturers
2.1 Global Rituxan (Rituximab) Monoclonal Antibody Sales Market Share by Manufacturers (2018-2023)
2.2 Global Rituxan (Rituximab) Monoclonal Antibody Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Rituxan (Rituximab) Monoclonal Antibody Average Price by Manufacturers (2018-2023)
2.4 Global Rituxan (Rituximab) Monoclonal Antibody Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Rituxan (Rituximab) Monoclonal Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rituxan (Rituximab) Monoclonal Antibody, Product Type & Application
2.7 Rituxan (Rituximab) Monoclonal Antibody Market Competitive Situation and Trends
2.7.1 Rituxan (Rituximab) Monoclonal Antibody Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Rituxan (Rituximab) Monoclonal Antibody Players Market Share by Revenue
2.7.3 Global Rituxan (Rituximab) Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Rituxan (Rituximab) Monoclonal Antibody Retrospective Market Scenario by Region
3.1 Global Rituxan (Rituximab) Monoclonal Antibody Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Rituxan (Rituximab) Monoclonal Antibody Global Rituxan (Rituximab) Monoclonal Antibody Sales by Region: 2018-2029
3.2.1 Global Rituxan (Rituximab) Monoclonal Antibody Sales by Region: 2018-2023
3.2.2 Global Rituxan (Rituximab) Monoclonal Antibody Sales by Region: 2024-2029
3.3 Global Rituxan (Rituximab) Monoclonal Antibody Global Rituxan (Rituximab) Monoclonal Antibody Revenue by Region: 2018-2029
3.3.1 Global Rituxan (Rituximab) Monoclonal Antibody Revenue by Region: 2018-2023
3.3.2 Global Rituxan (Rituximab) Monoclonal Antibody Revenue by Region: 2024-2029
3.4 North America Rituxan (Rituximab) Monoclonal Antibody Market Facts & Figures by Country
3.4.1 North America Rituxan (Rituximab) Monoclonal Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Rituxan (Rituximab) Monoclonal Antibody Sales by Country (2018-2029)
3.4.3 North America Rituxan (Rituximab) Monoclonal Antibody Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Rituxan (Rituximab) Monoclonal Antibody Market Facts & Figures by Country
3.5.1 Europe Rituxan (Rituximab) Monoclonal Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Rituxan (Rituximab) Monoclonal Antibody Sales by Country (2018-2029)
3.5.3 Europe Rituxan (Rituximab) Monoclonal Antibody Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rituxan (Rituximab) Monoclonal Antibody Market Facts & Figures by Country
3.6.1 Asia Pacific Rituxan (Rituximab) Monoclonal Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Rituxan (Rituximab) Monoclonal Antibody Sales by Country (2018-2029)
3.6.3 Asia Pacific Rituxan (Rituximab) Monoclonal Antibody Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Rituxan (Rituximab) Monoclonal Antibody Market Facts & Figures by Country
3.7.1 Latin America Rituxan (Rituximab) Monoclonal Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Rituxan (Rituximab) Monoclonal Antibody Sales by Country (2018-2029)
3.7.3 Latin America Rituxan (Rituximab) Monoclonal Antibody Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Rituxan (Rituximab) Monoclonal Antibody Market Facts & Figures by Country
3.8.1 Middle East and Africa Rituxan (Rituximab) Monoclonal Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Rituxan (Rituximab) Monoclonal Antibody Sales by Country (2018-2029)
3.8.3 Middle East and Africa Rituxan (Rituximab) Monoclonal Antibody Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Rituxan (Rituximab) Monoclonal Antibody Sales by Type (2018-2029)
4.1.1 Global Rituxan (Rituximab) Monoclonal Antibody Sales by Type (2018-2023)
4.1.2 Global Rituxan (Rituximab) Monoclonal Antibody Sales by Type (2024-2029)
4.1.3 Global Rituxan (Rituximab) Monoclonal Antibody Sales Market Share by Type (2018-2029)
4.2 Global Rituxan (Rituximab) Monoclonal Antibody Revenue by Type (2018-2029)
4.2.1 Global Rituxan (Rituximab) Monoclonal Antibody Revenue by Type (2018-2023)
4.2.2 Global Rituxan (Rituximab) Monoclonal Antibody Revenue by Type (2024-2029)
4.2.3 Global Rituxan (Rituximab) Monoclonal Antibody Revenue Market Share by Type (2018-2029)
4.3 Global Rituxan (Rituximab) Monoclonal Antibody Price by Type (2018-2029)
5 Segment by Application
5.1 Global Rituxan (Rituximab) Monoclonal Antibody Sales by Application (2018-2029)
5.1.1 Global Rituxan (Rituximab) Monoclonal Antibody Sales by Application (2018-2023)
5.1.2 Global Rituxan (Rituximab) Monoclonal Antibody Sales by Application (2024-2029)
5.1.3 Global Rituxan (Rituximab) Monoclonal Antibody Sales Market Share by Application (2018-2029)
5.2 Global Rituxan (Rituximab) Monoclonal Antibody Revenue by Application (2018-2029)
5.2.1 Global Rituxan (Rituximab) Monoclonal Antibody Revenue by Application (2018-2023)
5.2.2 Global Rituxan (Rituximab) Monoclonal Antibody Revenue by Application (2024-2029)
5.2.3 Global Rituxan (Rituximab) Monoclonal Antibody Revenue Market Share by Application (2018-2029)
5.3 Global Rituxan (Rituximab) Monoclonal Antibody Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Rituxan (Rituximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Roche Rituxan (Rituximab) Monoclonal Antibody Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Teva
6.2.1 Teva Corporation Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Rituxan (Rituximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Teva Rituxan (Rituximab) Monoclonal Antibody Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Rituxan (Rituximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer Rituxan (Rituximab) Monoclonal Antibody Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Corporation Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Rituxan (Rituximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amgen Rituxan (Rituximab) Monoclonal Antibody Product Portfolio
6.4.5 Amgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rituxan (Rituximab) Monoclonal Antibody Industry Chain Analysis
7.2 Rituxan (Rituximab) Monoclonal Antibody Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rituxan (Rituximab) Monoclonal Antibody Production Mode & Process
7.4 Rituxan (Rituximab) Monoclonal Antibody Sales and Marketing
7.4.1 Rituxan (Rituximab) Monoclonal Antibody Sales Channels
7.4.2 Rituxan (Rituximab) Monoclonal Antibody Distributors
7.5 Rituxan (Rituximab) Monoclonal Antibody Customers
8 Rituxan (Rituximab) Monoclonal Antibody Market Dynamics
8.1 Rituxan (Rituximab) Monoclonal Antibody Industry Trends
8.2 Rituxan (Rituximab) Monoclonal Antibody Market Drivers
8.3 Rituxan (Rituximab) Monoclonal Antibody Market Challenges
8.4 Rituxan (Rituximab) Monoclonal Antibody Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock